What OrsoBio’s Phase 1b/2a TLC-6740 results reveal about the limits of GLP-1 monotherapy
OrsoBio’s TLC-6740 combo data hints at a new way to break GLP-1 plateaus. Read what this could change in obesity drug development.
OrsoBio’s TLC-6740 combo data hints at a new way to break GLP-1 plateaus. Read what this could change in obesity drug development.